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MaBACKGROUND Arrhythmogenic right ventricular cardiomyopathy (ARVC) is associated with sudden cardiac death. How-
ever, the selection of patients for implanted cardioverter-deﬁbrillators (ICDs), as well as programming of the ICD, is unclear.
OBJECTIVES The objective of this study was to identify predictors, characteristics, and treatment of ventricular
arrhythmias in patients with ARVC.
METHODS The Multidisciplinary Study of Right Ventricular Cardiomyopathy established the North American ARVC
Registry and enrolled patients with a diagnosis of ARVC. Patients were followed prospectively.
RESULTS Of 137 patients enrolled, 108 received ICDs. Forty-eight patients had 502 sustained episodes of ventricular
arrhythmias, including 489 that were monomorphic and 13 that were polymorphic. In the patients with ICDs, independent
predictors of ventricular arrhythmias in follow-up included spontaneous sustained ventricular arrhythmias before ICD
implantation and T-wave inversions inferiorly. The only independent predictor for life-threatening arrhythmias, deﬁned as
sustained ventricular tachycardia (VT) $240 beats/min or ventricular ﬁbrillation, was a younger age at enrollment. Anti-
tachycardia pacing (ATP), independent of the cycle length of the VT, was successful in terminating 92% of VT episodes.
CONCLUSIONS In the North American ARVC Registry, the majority of ventricular arrhythmias in follow-up are mono-
morphic. Risk factors for ventricular arrhythmias were spontaneous ventricular arrhythmias before enrollment
and a younger age at ICD implantation. ATP is highly successful in terminating VT, and all ICDs should be programmed
for ATP, even for rapid VT. (J Am Coll Cardiol 2014;64:119–25) © 2014 by the American College of Cardiology Foundation.A rrhythmogenic right ventricular cardiomyop-athy (ARVC) is a cardiomyopathy associatedwith sudden cardiac death (SCD) (Central
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AND ACRONYMS
ARVC = arrhythmogenic right
ventricular cardiomyopathy
ATP = anti-tachycardia pacing
ECG = electrocardiogram/
electrocardiography
ICD = implantable
cardioverter-deﬁbrillator
LV = left ventricular
RV = right ventricular
SAECG = signal-averaged
electrocardiogram/
electrocardiography
SCD = sudden cardiac death
SMVT = sustained
monomorphic ventricular
tachycardia
SPVF = sustained polymorphic
ventricular ﬁbrillation
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120history of syncope (4–8). However, these risk
factors have not been consistent from study
to study. In addition, guidelines for appro-
priate ICD programming are lacking. The
North American Multidisciplinary Study of
Right Ventricular Cardiomyopathy/Dysplasia
was initiated in 2000 to clarify diagnostic
criteria and assess treatment of ARVC
(2,9,10). The focus of the current study is to
review the experience in this prospective
ARVC Registry.SEE PAGE 126METHODS
PATIENT POPULATION. At the enrolling
centers, patients were subject to 12-lead
electrocardiography (ECG), signal-averaged
electrocardiography (SAECG), 24-h Holtermonitoring, electrophysiology study with pro-
grammed ventricular stimulation, echocardiography,
RV angiography, RV free-wall and septal biopsies,
magnetic resonance imaging, and blood work for aRAL ILLUSTRATION Arrhythmogenic Right Ventricular Card
hmogenic right ventricle dysplasia, an inherited disease of the de
rant arrhythmias. ARVC ¼ arrhythmogenic right ventricular cardiogenetic analysis. The decision to implant an ICD and
all programming decisions were left to the discretion
of the individual physician and patient. Stored elec-
trograms were reviewed after any device therapy and
with each scheduled follow-up. All electrograms
were sent to the ICD core laboratory (Tufts Medical
Center, Boston, Massachusetts), where all therapies
were independently reviewed and classiﬁed by 2
electrophysiologists. Ventricular tachycardias were
characterized as monomorphic or polymorphic and
by cycle length.
STATISTICAL ANALYSIS. Descriptive characteristics
are provided as mean  SD and were compared by
means of the Student t test. Continuous variables
that were not normally distributed were reported
as median and interquartile range and were
compared with the use of the Wilcoxon rank-sum
test. Categorical variables were compared by
means of the chi-square analysis. The Cox propor-
tional hazard model was used to examine the 2
primary arrhythmic endpoints: 1) ICD-treated ven-
tricular arrhythmia, death, or transplantation; and
2) potentially life-threatening arrhythmia (deﬁnediomyopathy
smosomal proteins, causes sudden cardiac death as a result of
myopathy.
TABLE 1 Clinical and Electrophysiological Factors in Patients With ARVC Who Were
or Were Not Implanted With an ICD
Clinical Characteristics
ICD
(n ¼ 108)
No ICD
(n ¼ 29) p Value
Age at enrollment, yrs 40  14 39  14 NS
Female 43 (40) 13 (45) NS
Sustained VT or cardiac arrest 52 (48) 4 (14) <0.001
Syncope (without sustained VT/CA) 14 (13) 3 (10) 0.07
Sustained VT or CA or syncope 66 (61) 7 (24) <0.001
Inducibility at EPS 46 (43) 5 (17) 0.01
Inducibility at EPS without history of
sustained VT/CA
16 (15) 4 (14) NS
Inducibility at EPS without history of
sustained VT/CA/syncope
11 (10) 4 (14) NS
Nonsustained VT 17 (16) 2 (7) NS
Deﬁnite diagnosis of ARVC by original
Task Force Criteria
77 (71) 14 (48) 0.02
Diagnostic criteria points (1994 criteria) 4.3  1.1 3.7  1.0 0.05
Family history of ARVC 21 (21) 5 (21) NS
Antiarrhythmic agents after enrollment 53 (55) 8 (42) NS
Beta-blockers 80 (83) 14 (74) NS
RVEF (%), mean by MRI 43  12 46  8 0.79
LVEF (%), mean by MRI 58.1  6.1 57.7  4.1 NS
T-wave inversion V1 to V3 82 (76) 15 (52) 0.011
Abnormal SAECG 53 (62) 15 (65) NS
Values are mean  SD or n (%). Differences between the 2 groups were observed in prior sustained ventricular
arrhythmias, any prior sustained ventricular arrhythmia or syncope, inducibility at EPS, deﬁnite diagnosis of ARVC
by original Task Force Criteria, diagnostic criteria points (1994 criteria), and T-wave inversion V1 to V3.
ARVC ¼ arrhythmogenic right ventricular cardiomyopathy; CA ¼ cardiac arrest; EPS¼ electrophysiologic study;
ICD ¼ implantable cardioverter-deﬁbrillator; LVEF ¼ left ventricular ejection fraction; MRI ¼magnetic resonance
imaging; RVEF ¼ right ventricular ejection fraction; SAECG ¼ signal-averaged electrocardiogram;
VT ¼ ventricular tachycardia.
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121as ventricular tachycardia >240 beats/min or ven-
tricular ﬁbrillation), using only those patients who
had an ICD implanted. Univariate variables of
signiﬁcance were subject to multivariate stepwise
models. Values of p < 0.05 were considered
signiﬁcant.
RESULTS
PATIENT POPULATION. A total 137 patients were
enrolled in the ARVC registry. The mean age at
enrollment was 40  14 years. The presentation of the
patients included SMVT or cardiac arrest (n ¼ 56;
41%), and syncope without documented sustained
arrhythmias (n ¼ 17; 12%). Of these 137, 108 (78%)
underwent an ICD implantation. Implant complica-
tions occurred in 2 patients, including an RV perfo-
ration and an infection that did not require ICD
removal. During 3.3  1.7 years of follow-up, 48 pa-
tients with an ICD had the combined endpoint of
any ventricular arrhythmia, death, or transplantation,
including 22 with the endpoint of life-threatening
arrhythmias. In the patients not undergoing ICD
implantation, there were no SCDs or documented
sustained ventricular arrhythmia during a mean of
2.4  1.5 years of follow-up.
CHARACTERISTICS OF PATIENTS BEFORE RECEIV-
ING AN ICD VERSUS NO ICD. There was no differ-
ence in the mean age or sex of those who did or did
not receive an ICD (Table 1). Fifty-two of the 108
(48%) patients with ICDs had spontaneous SMVT or
sustained polymorphic ventricular ﬁbrillation
(SPVF) before ICD implantation, compared with 4 in
the non-ICD group (p < 0.001). An additional
14 (13%) had syncope in the group implanted with
ICDs, compared with 3 (10%) in the non-ICD group
(p ¼ 0.07). Other differences between the ICD pa-
tients and the non-ICD patients included a deﬁni-
tive diagnosis of ARVC, number of Task Force
Criteria points, and T-wave inversions in leads V1
to V3.
ENDPOINTS OF VENTRICULAR ARRHYTHMIA AFTER
ICD IMPLANTATION. Of the 108 patients who
received an ICD, 48 had ventricular arrhythmias
treated by the ICD during follow-up (Table 2, Fig. 1).
In a multivariate analysis, the only 2 predictors
of ICD treatment of ventricular arrhythmias were pre-
implantation SMVT or SPVF (p ¼ 0.0029) and T-wave
inversions inferiorly (p ¼ 0.0159). There were no
sudden deaths in the cohort with ICDs or in the cohort
who did not receive ICDs.
ENDPOINT OF LIFE-THREATENING ARRHYTHMIAS
(VENTRICULAR TACHYCARDIA ‡240 BEATS/MIN,
VENTRICULAR FIBRILLATION, OR SCD). Twenty-two individuals had the occurrence of rapid SMVT
($240 beats/min) or SPVF after ICD implantation
(Table 3). In a multivariate analysis, only younger age
at the time of ICD implantation was predictive of life-
threatening ventricular arrhythmias (p ¼ 0.032).
ICD TREATMENT OF VENTRICULAR ARRHYTHMIAS
DURING FOLLOW-UP. Forty-eight patients had 502
sustained episodes of ventricular arrhythmias,
including 489 SMVT and 13 SPVF. The mean cycle
length of the SMVT was 317  39 ms and the mean
cycle length of the SPVF was 216  40 ms. Of the
489 monomorphic ventricular arrhythmias, 450
were treated with anti-tachycardia pacing (ATP) and
412 (92%) were successfully terminated with ATP.
Thirty-eight arrhythmias did not respond to ATP and
were treated with a shock. There was no difference
in the cycle length of the SMVT successfully treated
(320  36 ms) versus those unsuccessfully treated
with ATP (320  45 ms) (Fig. 2). Of the SMVT cycle
lengths from 200 to 250 ms, 11 of 12 (92%) were
successfully treated with ATP, compared with 27 of
32 (84%) with cycle lengths from 251 to 275 ms, 90
of 97 (93%) with cycle lengths of 276 to 300 ms, 115
of 125 (92%) with cycle lengths of 301 to 320 ms, and
TABLE 2 Predictors of Ventricular Arrhythmias in the 108 Patients With ICDs
Clinical Characteristics
No Arrhythmia
(n ¼ 60)
Arrhythmia
(n ¼ 48) p Value
Age at enrollment, yrs 41  14 38  14 0.413
Age at earliest symptom, yrs 37  14 35  15 0.609
Female 27 (45) 16 (33) 0.218
Affected (by Task Force Criteria) 37 (62) 40 (83) 0.013
Diagnostic criteria points (1994 criteria) 4.2  1.0 4.3  1.2 0.84
Arrhythmic events (VT/VF)
before enrollment
34 (57) 45 (94) <0.001
Syncope before enrollment 14 (23) 14 (29) 0.492
Syncope or VT/VF before enrollment 36 (60) 46 (96) <0.001
Family history of sudden death 22 (42) 16 (36) 0.960
Follow-up, yrs 3.0  1.8 3.5  1.5 0.114
Heart transplant 2 (3) 1 (2) 1.000
Death 1 (2) 1 (2) 1.000
Antiarrhythmic drug treatment 19 (39) 34 (72) <0.001
Beta-blockers 41 (84) 39 (83) 0.927
RVEF (%) by MRI, mean 43  11 43  13 0.334
LVEF (%) by MRI, mean 59.74  6.42 55.65  4.79 0.009
Negative T-wave in leads II, III, aVF 19 (32) 33 (69) <0.001
QRS duration in V2, mean 0.103  0.023 0.108  0.021 0.055
fQRS40, mean 116.9 126.5 0.011
fQRS40 >120 16 (33) 21 (55) 0.041
VPBs (ventricular total >1,000/24 h) 25 (58) 18 (51) 0.553
Any induced VT or VF 30 (50) 33 (69) 0.050
Values are mean  SD or n (%). Predictors of arrhythmias after ICD implantation included deﬁnite diagnosis of
ARVC, VT/VF before enrollment, syncope or VT/VF before enrollment, antiarrhythmic drug treatment, negative
T-wave in leads II, III, aVF, abnormal SAECG by fQRS40 mean and >140 ms, induced VT/VF. The 2 independent
predictors of ICD treatment of ventricular arrhythmias were pre-implantation sustained VT/VF (p ¼ 0.0029) and
T-wave inversions inferiorly (p ¼ 0.0159).
EPS ¼ electrophysiologic study; VPB ¼ ventricular premature beat; VF ¼ ventricular ﬁbrillation; other
abbreviations as in Table 1.
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Sust VT/VF/CA 52 25 (0.50) 17 (0.60) 11 (0.60)
Syncope 14 11 (0.21) 7 (0.43) 3 (0.43)
Palp/Asympt 42 31 (0.13) 22 (0.19) 18 (0.23)
FIGURE 1 Time to Cardiac Arrhythmia
Kaplan-Meier graph of time to ﬁrst cardiac arrhythmia with the groups divided according
to their clinical presentation; sustained ventricular tachycardia (VT) or cardiac arrest
(CA), syncope without documented sustained arrhythmias, or palpitations/asymptomatic.
Event rates in those with sustained VT or CA was 3.91 per year compared with 1.48 per
year in those with syncope and 0.79 per year in those asymptomatic or with palpitations.
Asymt ¼ asymptomatic; ICD ¼ implantable cardioverter-deﬁbrillator; Palp ¼ palpitations;
Sust ¼ sustained; VF ¼ ventricular ﬁbrillation.
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122159 of 174 (91%) with cycle lengths of >320 ms. Fifty
VTs were treated with a shock initially (cycle lengths
of 256  40 ms) because of the lack of ATP pro-
gramming for the rate of the VT. All episodes of
SMVT and VF were successfully terminated with a
shock.
INAPPROPRIATE THERAPY WITH THE ICD. Seven-
teen individuals had inappropriate ICD therapy,
including 2 for nonsustained ventricular tachycardia,
14 for sinus tachycardia, 7 for atrial ﬁbrillation, 16 for
other supraventricular tachycardias, 1 for lead noise,
and 3 for oversensing. There was no difference in
these groups with regard to age at enrollment, age
with earlier symptom(s), sex, appropriate arrhythmic
events, history of syncope, use of antiarrhythmic
drugs, or beta-blockers.
DISCUSSION
In this analysis of the North American ARVC Registry,
ventricular arrhythmias, including those deﬁned as
life-threatening, occurred in nearly 50% of patients
who received an ICD. Predictors of ICD-treated ven-
tricular arrhythmias were predominantly the occur-
rence of prior SMVT or SPVF, although T-wave
inversions were a predictor of any ventricular ar-
rhythmia in follow-up and a younger age predicted
for SPVF. These data support the use of ICDs in ARVC.
The observation that there were no deaths in the
29 patients without ICDs indicates that patients
without spontaneous ventricular arrhythmias or
syncope may have a reasonable prognosis without
ICDs. This study also offers guidance for program-
ming an ICD. In patients with ARVC, the arrhythmias
were predominantly monomorphic VT. ATP was
successful in terminating 92% of the SMVTs, and
its success did not depend on the rapidity of the
SMVT.
PRIOR STUDIES ON PREDICTORS OF SCD AND
ARRHYTHMIAS IN ARVC. Previous studies that
evaluated predictors of arrhythmias in ARVC were
based on retrospective analyses (11). In a multi-
center trial of 132 ICD patients (13 [10%] of whom
had prior cardiac arrest, 82 [62%] had sustained
ventricular tachycardia, and 21 [16%] had syncope),
nearly one-half had ventricular arrhythmias in a
follow-up of 39  25 months (8). Predictors of life-
threatening arrhythmias (SMVT >240 beats/min or
SPVF) were a history of either cardiac arrest or
SMVT with hemodynamic compromise, younger
age, and left ventricular involvement. Inducible
SMVT did not predict SMVT in follow-up. In 42
ICD patients followed for 42  26 months, 33 had
ventricular arrhythmias (92% SMVT) (6). Predictors
TABLE 3 Predictors of Life-Threatening VT/VF in the Patients With ICDs
Clinical Characteristics
No Arrhythmia
(n ¼ 60)
Fast Arrhythmia VT/VF
(n ¼ 22)
p Value
No Arrhythmia Vs.
Fast Arrhythmias
No Fast Arrhythmia Vs.
Fast Arrhythmias
Age at enrollment 41  14 33  15 0.036 0.032
Age at earliest symptom, yrs 37  14 31  17 0.140 0.130
Female 27 (45) 5 (25) 0.114 0.132
Affected 37 (62) 18 (90) 0.018 0.066
Arrhythmic events (VT/VF) before enrollment 34 (57) 19 (95) 0.002 0.020
Syncope before enrollment 14 (23) 8 (40) 0.148 0.151
Syncope or VT/VF 36 (60) 19 (95) 0.003 .040
Family history of sudden death 22 (42) 7 (37) 1.000 0.970
Follow-up, yrs 3.0  1.8 3.8  1.1 0.074 0.185
Heart transplant 2 (3) 0 (0) 1.000 1.000
Death 1 (2) 0 (0) 1.000 1.000
Antiarrhythmic agents 19 (39) 14 (70) 0.018 0.169
Beta-blockers 41 (84) 17 (85) 1.000 1.000
RVEF (%), mean, MRI 43  8 41  13 0.237 0.284
LVEF (%), mean, MRI 59.74  6.42 55.67  4.69 0.041 0.131
Negative T-wave in leads II, III, aVF 19 (32) 12 (60) 0.024 0.296
QRS duration in V2 0.103  0.023 0.106  0.023 0.292 0.693
Filtered QRS40, mean 116.9 123.4 0.172 0.552
fQRS40 >120 16 (33) 8 (53) 0.164 0.451
VPBs (ventricular total >1,000/24 h) 25 (58) 9 (64) 0.684 0.560
Any induced VT or VF 30 (50) 13 (65) 0.244 0.625
Values are mean  SD or n (%). The fourth column compares those with no ventricular arrhythmia with those with only fast ventricular arrhythmias; the ﬁfth column compares
those without fast VT/VF with those with fast VT/VF. Predictors of life-threatening VT/VF included younger age at enrollment, VT/VF before enrollment, and syncope or VT/VF
before enrollment. The only independent predictor was younger age at the time of ICD implantation (p ¼ 0.032).
Abbreviations as in Tables 1 and 2.
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123of arrhythmias in the study included spontaneous
or induced ventricular arrhythmias. Syncope and
family history of ARVC did not predict SMVT or
SPVF. Another 60 ICD patients (most with SMVT,
SPVF, or syncope) followed for 80  43 months had
no predictors of ventricular arrhythmias (5).
In a more recent publication of 106 ICD patients
without prior sustained ventricular arrhythmias or0
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FIGURE 2 Success of Anti-Tachycardia Pacing in the Termination of
of Arrhythmia in Milliseconds
Even rapid ventricular tachycardias had a high likelihood of terminationSCD (Darvin II), only unexplained syncope was a
predictor of ventricular arrhythmias (4).
In a study that included patients without ICDs,
313 patients were followed for 8.5 years, with an
annual mortality rate of 0.3% (12). The major risk for
death was reduced left ventricular function. In
another cohort of ARVC patients, including 61 pa-
tients not treated with ICDs, congestive heart failure-300 251-275 200-250
Ventricular Tachycardia Stratiﬁed by Cycle Length
with anti-tachycardia pacing.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE 1:
VT in patients with ARVC is more often monomorphic
than polymorphic.
COMPETENCY IN MEDICAL KNOWLEDGE 2:
In patients with ARVC with ICDs, sustained ventricular
arrhythmias before device implantation and T-wave
inversions in the inferior electrocardiographic leads
are independent predictors of ventricular arrhythmias.
COMPETENCY IN PATIENT CARE: Anti-
tachycardia pacing successfully terminated most
VT episodes regardless of the heart rate and should
be programmed for all patients.
TRANSLATIONAL OUTLOOK 1: Additional studies
are needed to identify predictors of less common
polymorphic VT in patients with ARVC.
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124and left ventricular involvement were predictors
for SCD (13). Finally, in a study that included 84
patients with ARVC who did not have clinical SMVT
or SPVF, inducibility at electrophysiologic study
and non-sustained ventricular tachycardia were in-
dependent predictors of ICD therapy for ventricular
arrhythmias (14).
APPROPRIATE ENDPOINTS. In most of the ARVC
studies, the primary endpoint has been that of ven-
tricular arrhythmias treated by an ICD. However,
treated ventricular arrhythmias do not necessarily
equate with SCD in the absence of an ICD. In an
analysis of randomized, controlled trials in which
patients with idiopathic heart failure with ICDs were
compared with patients without ICDs, the number
of ICD-treated arrhythmias was 2- to 3-fold the SCD
risk in the control arm (15). Thus, the life-saving
beneﬁt of the ICD is overestimated if equated with
any ventricular arrhythmia treated by the ICD.
Although we attempted to more closely approxi-
mate SCD by including an analysis restricted to po-
tential life-threatening arrhythmias deﬁned as $240
beats/min, this deﬁnition may overestimate the inci-
dence of SCD, especially in patients with ARVC who
frequently have normal LV function and can tolerate
rapid VT for hours or longer. In addition, rapid VT
may terminate spontaneously if left untreated.
IMPLICATIONS FOR THE PROGRAMMING OF ICDS.
The vast majority of ventricular arrhythmias in ARVC
patients in this registry were SMVT (97%), some with
very rapid rates. However, in this study, even rapid
SMVT (at 200 to 250 ms cycle length) was terminated
with ATP. Of those arrhythmias in which ATP was
attempted, most patients were successfully treated
with ATP, and the success of ATP was not dependent
on the cycle length. Thus, ATP should be programmed
for all patients with ARVC and should include ATP,
even for rapid VT.TRANSLATIONAL OUTLOOK 2: The efﬁcacy of
anti-tachycardia pacing and optimum device settings
for patients with ARVC should be evaluated in pro-
spective studies.CONCLUSIONS
The North American Multidisciplinary Study in Right
Ventricular Cardiomyopathy is the ﬁrst prospectivelydeﬁned registry to evaluate the risk factors of ar-
rhythmias and sudden death in patients with ARVC.
Most of the individuals in this registry were treated
with an ICD, and approximately one-half received
ICD therapy for SMVT, whereas one-ﬁfth of patients
were treated for rapid SMVT or SPVF. Risk factors for
ventricular arrhythmias were spontaneous ventricu-
lar arrhythmias before enrollment and a younger age
at time of ICD implantation. When an ICD is placed,
ATP is highly successful in terminating SMVT and
should be programmed for all SMVT, regardless of
heart rate.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Mark S. Link, Tufts Medical Center Box #197, 800
Washington Street, Boston, Massachusetts 02459.
E-mail: mlink@tuftsmedicalcenter.org.RE F E RENCE S1. Basso C, Corrado D, Marcus FI, et al. Arrhyth-
mogenic right ventricular cardiomyopathy. Lancet
2009;373:1289–300.
2. Marcus FI, Zareba W, Calkins H, et al. Arrhythmo-
genic right ventricular cardiomyopathy/dysplasia
clinical presentation and diagnostic evaluation: re-
sults from the North American Multidisciplinary
Study. Heart Rhythm 2009;6:984–92.3. Marcus FI, Fontaine G. Arrhythmogenic right
ventricular dysplasia/cardiomyopathy: a review.
Pacing Clin Electrophysiol 1995;18:1298–314.
4. Corrado D, Calkins H, Link MS, et al. Prophylactic
implantable deﬁbrillator in patients with arrhythmo-
genic right ventricular cardiomyopathy/dysplasia and
no prior ventricular ﬁbrillation or sustained ventric-
ular tachycardia. Circulation 2010;122:1144–52.5. Wichter T, Paul M, Wollmann C, et al. Implant-
able cardioverter/deﬁbrillator therapy in arrhy-
thmogenic right ventricular cardiomyopathy:
single-center experience of long-term follow-up
and complications in 60 patients. Circulation
2004;109:1503–8.
6. Roguin A, Bomma CS, Nasir K, et al. Implantable
cardioverter-deﬁbrillators in patients with
J A C C V O L . 6 4 , N O . 2 , 2 0 1 4 Link et al.
J U L Y 1 5 , 2 0 1 4 : 1 1 9 – 2 5 ARVC and Arrhythmias
125arrhythmogenic right ventricular dysplasia/
cardiomyopathy. J Am Coll Cardiol 2004;43:1843–52.
7. Nava A, Bauce B, Basso C, et al. Clinical proﬁle
and long-term follow-up of 37 families with
arrhythmogenic right ventricular cardiomyopathy.
J Am Coll Cardiol 2000;36:2226–33.
8. Corrado D, Leoni L, Link MS, et al. Implantable
cardioverter-deﬁbrillator therapy for prevention
of sudden death in patients with arrhythmogenic
right ventricular cardiomyopathy/dysplasia. Cir-
culation 2003;108:3084–91.
9. Marcus F, Towbin JA, Zareba W, et al.
Arrhythmogenic right ventricular dysplasia/car-
diomyopathy (ARVD/C): a multidisciplinary
study: design and protocol. Circulation 2003;
107:2975–8.
10. Marcus GM, Glidden DV, Polonsky B, et al.
Efﬁcacy of antiarrhythmic drugs in arrhythmogenicright ventricular cardiomyopathy: a report from
the North American ARVC Registry. J Am Coll
Cardiol 2009;54:609–15.
11. Link MS, Wang PJ, Haugh CJ, et al. Arrhyth-
mogenic right ventricular dysplasia: clinical results
with implantable cardioverter deﬁbrillators.
J Interv Card Electrophysiol 1997;1:41–8.
12. Peters S. Long-term follow-up and risk
assessment of arrhythmogenic right ventricular
dysplasia/cardiomyopathy: personal experience
from different primary and tertiary centres.
J Cardiovasc Med 2007;8:521–6.
13. Lemola K, Brunckhorst C, Helfenstein U,
et al. Predictors of adverse outcome in
patients with arrhythmogenic right ventricular
dysplasia/cardiomyopathy: long term experi-
ence of a tertiary care centre. Heart 2005;91:
1167–72.14. Bhonsale A, James CA, Tichnell C, et al.
Incidence and predictors of implantable
cardioverter-deﬁbrillator therapy in patients
with arrhythmogenic right ventricular
dysplasia/cardiomyopathy undergoing implant-
able cardioverter-deﬁbrillator implantation for
primary prevention. J Am Coll Cardiol 2011;58:
1485–96.
15. Ellenbogen KA, Levine JH, Berger RD, et al. Are
implantable cardioverter-deﬁbrillator shocks a
surrogate for sudden cardiac death in patients
with nonischemic cardiomyopathy? Circulation
2006;113:776–82.
KEY WORDS arrhythmogenic right
ventricular cardiomyopathy, implantable
cardioverter-deﬁbrillator, ventricular
arrhythmia, ventricular tachycardia
